Shinshu University

Event

Lecture

11/04/2010
¢£GCOE¢£Special lecture by Dr. Hiromi Sakai, Principal investigator, WASEDA Bioscience Research Institute in Singapore (WABIOS)/Associate Professor, Comprehensive Research Organization, Waseda University.
22nd November 2010.

*Co-hosted by International Young Researchers Empowerment Center

GCOE Program Leader,
Toshihiro Hirai

On 22nd November 2010, Global COE, International Center of Excellence on Fiber Engineering, and International Young Researchers Empowerment Center will hold special lecture by Prof. Dr. Hiromi Sakai from Waseda Bioscience Research Institute in Singapore (WABIOS) / Comprehensive Research Organization, Waseda University.
Please see details given below.
(*We encourage ALL doctoral students who major in International Fiber Engineering course to attend this special lecture.)

Date ¡§November 22, 2010 (Mon) 15:30 ¡Á16:30

Place¡§Shinshu University, FTST¡¡Lecture Room 31

Title: Developments and current situation of artificial red cells (Hemoglobin vesicles)

Lecturer¡§ Hiromi Sakai, Dr. Eng., Dr. Med. Sci.
Principal Investigator, WASEDA Bioscience Research Institute in Singapore(WABIOS)
Associate Professor, Comprehensive Research Organization, Waseda University

Summary : Blood transfusion systems have greatly benefited human health and welfare. Nevertheless, some problems remain: infection, blood type mismatching, immunological response, short shelf life, and screening test costs. Blood substitutes have been under development for decades to overcome such problems. Plasma component substitutes have already been established: plasma expanders, electrolytes, and recombinant coagulant factors. Herein, we focus on the development of red blood cell substitutes. Side effects hindered early development of cell-free hemoglobin (Hb)-based oxygen carriers (HBOCs) and underscored the physiological importance of the cellular structure of red blood cells (RBCs). Well-designed artificial oxygen carriers that meet requisite criteria are expected to be realized eventually. Encapsulation of Hb is one idea to shield the toxicities of molecular Hbs. However, intrinsic issues of encapsulated Hbs must be resolved: difficulties related to regulating the molecular assembly, and management of its physicochemical and biochemical properties. Hb-vesicles (HbV) are a cellular type of HBOC that overcome these issues. The in vivo safety and efficacy of HbV have been studied extensively. The results illustrate the potential of HbV as a transfusion alternative and promise its use for other clinical applications that remain unattainable using RBC transfusion.

HP:http://www.waseda.jp/WABIOS/CV/Sakai-summary.pdf

All are very welcome to attend this lecture.
³«ºÅÆü 2010.11.22
³«ºÅ»þ´Ö 15:30¡Á16:30